# Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

> **NCT05561374** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Oblato, Inc.** · enrollment: 16 (estimated)

## Conditions studied

- High-grade Glioma
- Oligodendroglioma
- Astrocytoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** Low-dose OKN-007, BID
- **DRUG:** Low-dose OKN-007, TID
- **DRUG:** Mid-dose OKN-007, TID
- **DRUG:** High-dose OKN-007, TID

## Key facts

- **NCT ID:** NCT05561374
- **Lead sponsor:** Oblato, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-17
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05561374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05561374, "Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05561374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*